Monday's Top 10 Articles, Videos on TheStreet

NEW YORK ( TheStreet) -- In case you missed them, here are the top 10 most popular articles and videos on TheStreet today. Sign up for free email delivery of our daily Top 10.

Stocks Tripped Up by Weak Employment Report
Andrea Tse
The Dow falls more than 150 points after a poor read on job creation in March raises fresh doubts about the pace of the economy's recovery.

Analysts' Actions: AAPL, TYC, FFIV
TheStreet Staff
Here are today's top research calls.

Spectrum Pharma: The Growth Party Is Over
Adam Feuerstein
The purchase of Allos Therapeutics cannot make up for the loss of Spectrum's bladder cancer drug. (Stocks include SPPI, ALTH, GILD)

Bristol-Gilead Hep C Drug Data Leaks
Adam Feuerstein
Partial results from a mid-stage study of hepatitis C drugs from Bristol and Gilead was leaked in advance of a key meeting in two weeks.

2 Ex-Dividend Stocks With Buy Ratings
Alexandra Zendrian
These stocks, which go ex-dividend Tuesday, are rated buy at TheStreet Ratings.

Downgrades Roundup: TDS, SEM, UAL, PKX, UBS, BBY
Alexandra Zendrian
These stocks received downgrades by TheStreet Ratings last week.

QE3 Is Still Coming
Roger Arnold
When the next round is required, I expect the Fed will attempt to drive down loan rates with the least amount of balance-sheet expansion as possible.

In Merger Talk, Always Question 'Cost Savings'
Marek Fuchs
The media needs to ask where 'cost savings' come from.

Upgrades Roundup: PRI, CYOU, GA, VCO, BID, SPIL, SSNC, TM, VRX, JNJ
Alexandra Zendrian
These stocks received upgrades to buy at TheStreet Ratings last week.

Sales Accelerate for Electric Cars
Anton Wahlman
A bump in March sales shows Volt is outstripping the competition.

This article was written by a staff member of TheStreet.

If you liked this article you might like

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Merger Buzz Drives Akorn to Top of Health Chart in April

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Biotech Premarket Movers: Spectrum, BioCryst, Curis

Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting